Anesiva, Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: South San Francisco CA United States (1999)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2001
NCT00041925
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Corgentech

Active Ingredients

Drugs in Phase 3 Trials (4)

Key: Anesiva, Inc. (2) Acquired (2)

4975 (Adlea) (2 trials)

capsaicin (qutenza) (9 trials)

edifoligide (3 trials)

lidocaine (xylocaine) (3 trials)

Drugs in Phase 2 Trials (2)

Key: Anesiva, Inc. (1) Acquired (1)

clonidine (catapres) (1 trial)

nf-kappab decoy (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Graft Occlusion, Vascular (Phase 3)

Hallux Valgus (Phase 3)

Hyperplasia (Phase 3)

Ischemia (Phase 3)

Kidney Failure, Chronic (Phase 2)

Myocardial Ischemia (Phase 3)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Peripheral Arterial Disease (Phase 3)

Peripheral Vascular Diseases (Phase 3)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 6